Mefeda

Methylphenidate Hydrochloride, the active ingredient in Mefeda, is a central nervous system stimulant presented as an oral tablet for oral use. It treats attention deficit hyperactivity disorder (ADHD) and narcolepsy in children, adolescents and adults, and is regulated as a Schedule II controlled substance available only by prescription.

GNH USA supplies Mefeda as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and reliable delivery.

Mefeda (methylphenidate hydrochloride) acts on the central nervous system to improve attention and wakefulness in the following conditions: - Attention deficit hyperactivity disorder (children): improves concentration, reduces impulsivity and hyperactivity. - Attention deficit hyperactivity disorder (adults): enhances focus and diminishes disruptive behavior. - Narcolepsy: decreases excessive daytime sleepiness and reduces the frequency of cataplexy episodes.

Mefeda may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced hunger leading to weight loss. - Headache: mild to moderate cranial pain. - Nausea: feeling of sickness or urge to vomit.

Serious or Rare Side Effects: - Cardiovascular events: chest pain, hypertension, or arrhythmia. - Psychosis: hallucinations or delusional thinking. - Severe allergic reaction: rash, swelling, or difficulty breathing.

Before initiating therapy with Mefeda, consider the following safety measures: - Cardiovascular assessment: evaluate heart disease or hypertension history. - Psychiatric monitoring: watch for new or worsening anxiety, mood swings, or psychotic symptoms. - Growth tracking: monitor weight and height in pediatric patients. - Substance‑use history: avoid in individuals with known stimulant misuse. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct heat.

Mefeda can interact with several medication classes; awareness of these interactions helps minimize risk.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Antihypertensive agents: may blunt blood‑pressure‑lowering effects. - Tricyclic antidepressants: increased risk of cardiovascular side effects.

Moderate Interactions (Monitor Closely):\n- Selective serotonin reuptake inhibitors (SSRIs): potential for serotonin syndrome. - Antihistamines: may enhance sedation or impair attention. - Alcohol and caffeine: can exacerbate cardiovascular stimulation and insomnia.